Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization

Inclusion Criteria: * Active duty, male subject, 17-35 years of age, inclusive, at the time of screening. * Assigned to one of the selected companies/battalions * Informed of the nature of the study and has agreed to and is able to read, review, and sign the informed consent document prior to screening. * Free of known significant health problems as established by the requirements to be enrolled in a military training program before entering into the study. * Agrees to be reachable by phone, email or letter at 6 months post-vaccination. Exclusion Criteria: * Reports receiving any investigational drug, investigational vaccine, or investigational device within 30 days prior to dosing; subjects will be allowed to receive routine vaccinations associated with training and any other prescribed medications not in the exclusion criteria. * Presence of clinically significant SSTI (e.g., cellulitis, abscess) at screening or other skin or skin structure infections that would confound the interpretation of clinical response. * Reports a history of allergic response(s), anaphylaxis, or other serious reactions to previous vaccinations. * Reports a history of allergies to yeast * Reports a history of anaphylaxis or other serious reactions to aluminum. * Reports a history of autoimmune disease (psoriasis, etc.) * Seropositive for HIV antibody. * Reports the use of any immunosuppressive drugs, including systemic corticosteroids (more than 14 days at a dose of \>20 mg/day prednisone or equivalent), within 4 weeks prior to dosing. * Reports receiving any blood products within 3 months prior to dosing. * Reports donating blood/plasma within 28 days prior to dosing. * Illness causing temperature ≥ 100.4°F * Evidence of abnormal, unresolved laboratory results in the subject's medical record for the following tests: hemoglobin, white blood cell count, platelet count, creatinine, and alanine aminotransferase * Any other medical and/or social reason which, in the opinion of the investigator(s), would increase the subject's risk of having an adverse reaction as a result of participation in the study.